Voriconazole Autoinduction and Saturable Metabolism After Cessation of Rifampin in a Patient With Invasive Central Nervous System Aspergillus: Importance of Therapeutic Drug Monitoring

Journal of Pharmacy Practice
Salia Farrokh, Edina Avdic

Abstract

Optimization of antifungal therapy with voriconazole can be challenging due to inter- and intrapatient variability in voriconazole pharmacokinetics (PK). In this case, we introduce challenges in voriconazole therapy due to drug-drug interactions, autoinduction, and saturable metabolism. A 32-year-old male on chronic prednisone developed central nervous system (CNS) aspergillosis. He was started on high-dose intravenous (IV) voriconazole 8.5 mg/kg every 12 hours due to concerns for lasting induction effects of recent rifampin therapy. The initial voriconazole trough was 2 μg/mL. Frequent dose adjustments were made to maintain the therapeutic trough goal. On day 24 of voriconazole therapy, his trough was undetectable on IV voriconazole 5.5 mg/kg every 12 hours. His dose was escalated to 8.5 mg/kg every 12 hours to avoid subtherapeutic levels and therapeutic failure. On day 48, his trough level was 1.1 μg/mL on the same dose. His regimen was changed to 6.5 mg/kg every 8 hours at this point. Sixteen days after this regimen on day 74 of voriconazole therapy, his trough was 27.2 μg/mL indicating saturable PK of voriconazole in the absence of interacting drugs. Our findings highlight the unpredictable PK of voriconazole and reinforce ...Continue Reading

References

Mar 1, 1970·Medicine·R C YoungV T DeVita
Jul 4, 2001·Clinical Pharmacokinetics·W J BurmanC Peloquin
Jan 25, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David W DenningHartmut Lode
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·L PurkinsD Kleinermans
May 21, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·S J RoffeyN Wood
Jul 29, 2003·Clinical Pharmacokinetics·Mikko NiemiKari T Kivistö
Jun 29, 2006·Clinical Pharmacokinetics·Ursula TheuretzbacherHartmut Derendorf
Sep 7, 2007·The Journal of Infection·Victor MulanovichDimitrios P Kontoyiannis
Nov 27, 2008·Journal of Clinical Pharmacology·Johanna WeissGerd Mikus
Jan 28, 2009·Antimicrobial Agents and Chemotherapy·Brad MoriyamaThomas J Walsh
Apr 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger J M BrüggemannDavid M Burger
Jan 20, 2015·Annals of Internal Medicine·Kieren A MarrJohan A Maertens
Apr 18, 2015·Pharmacotherapy·Alice Jenh HsuRavit Arav-Boger
Feb 18, 2016·Antimicrobial Agents and Chemotherapy·M A Encalada VenturaJ W C Alffenaar
Aug 3, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas F PattersonJohn E Bennett
Sep 8, 2016·The Journal of Antimicrobial Chemotherapy·Anette VeringaJan-Willem C Alffenaar
Sep 22, 2017·Drug, Healthcare and Patient Safety·Martin J FergusonDeclan G de Freitas

❮ Previous
Next ❯

Citations

Jun 22, 2021·Antimicrobial Agents and Chemotherapy·Xueke TianXiaojian Zhang
Dec 20, 2021·Therapeutic Drug Monitoring·Benjamin KablyEliane M Billaud

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Revista de medicina de la Universidad de Navarra
I Gil-AldeaJ R Azanza
The Medical Letter on Drugs and Therapeutics
Expert Opinion on Drug Safety
A C PasqualottoRafael Linden
© 2022 Meta ULC. All rights reserved